ATE318896T1 - Rekombinante rna-replikase von hepatitis-c-virus - Google Patents

Rekombinante rna-replikase von hepatitis-c-virus

Info

Publication number
ATE318896T1
ATE318896T1 AT96933178T AT96933178T ATE318896T1 AT E318896 T1 ATE318896 T1 AT E318896T1 AT 96933178 T AT96933178 T AT 96933178T AT 96933178 T AT96933178 T AT 96933178T AT E318896 T1 ATE318896 T1 AT E318896T1
Authority
AT
Austria
Prior art keywords
hcv
rdrp
hepatitis
virus
vitro
Prior art date
Application number
AT96933178T
Other languages
English (en)
Inventor
Curt H Hagedorn
Reinoldus H Al
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE318896T1 publication Critical patent/ATE318896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
AT96933178T 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus ATE318896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27

Publications (1)

Publication Number Publication Date
ATE318896T1 true ATE318896T1 (de) 2006-03-15

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933178T ATE318896T1 (de) 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus

Country Status (8)

Country Link
US (2) US5981247A (de)
EP (1) EP0859833B1 (de)
JP (1) JP4191797B2 (de)
AT (1) ATE318896T1 (de)
AU (1) AU719122B2 (de)
CA (1) CA2233309A1 (de)
DE (1) DE69635864T2 (de)
WO (1) WO1997012033A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
US6228576B1 (en) 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
EP1058686B1 (de) 1998-02-25 2006-11-02 Emory University 2'-fluoronukleoside
AU768177B2 (en) * 1998-04-02 2003-12-04 Viropharma Incorporated Hepatitis C virus NS5B compositions and methods of use thereof
AU4393399A (en) 1998-06-24 2000-01-10 Chugai Seiyaku Kabushiki Kaisha Hcv-derived rna polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
AU764095B2 (en) * 2000-04-07 2003-08-07 Shionogi & Co., Ltd. Preincubation assay method
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
MXPA03006634A (es) * 2001-01-31 2003-10-15 Bristol Myers Squibb Pharma Co Sistema in vitro para replicacion de virus de acido ribonucleico polimerasa dependiente del acido ribonucleico.
JP4338402B2 (ja) * 2001-05-22 2009-10-07 ユニバーシティ オブ シカゴ Ｎ４ウイルス一本鎖ｄｎａ依存的ｒｎａポリメラーゼ
WO2003025156A2 (en) * 2001-09-18 2003-03-27 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
US20030104445A1 (en) * 2001-09-25 2003-06-05 Hayes Robert J. RNA dependent RNA polymerase mediated protein evolution
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
AU2002360394A1 (en) * 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
ES2469569T3 (es) 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
LT2604620T (lt) 2003-05-30 2016-09-12 Gilead Pharmasset Llc Modifikuoti fluorintų nukleozidų analogai
KR20060084845A (ko) 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
WO2005070957A1 (en) * 2004-01-09 2005-08-04 Merck & Co., Inc. Hcv rna-dependent rna polymerase
US7414031B2 (en) 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
CA2597685A1 (en) 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside compounds for treating viral infections
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
CA2729168A1 (en) 2008-07-02 2010-02-04 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
PA8855701A1 (es) 2008-12-23 2010-07-27 Análogos de nucleósidos
JP5713919B2 (ja) 2008-12-23 2015-05-07 ギリアド ファーマセット エルエルシー ヌクレオシドホスホラミデート
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
CN102713630A (zh) 2009-11-14 2012-10-03 弗·哈夫曼-拉罗切有限公司 用于预测对hcv治疗的快速应答的生物标志物
SG181104A1 (en) 2009-12-02 2012-07-30 Hoffmann La Roche Biomarkers for predicting sustained response to hcv treatment
EP2752422B1 (de) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselektive synthese von phosphorhaltigen wirkstoffen
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
BR112013001516A2 (pt) 2010-07-22 2016-06-07 Novartis Ag compostos de tiofeno 2,3,5-trissubstituídos e empregos destes
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (de) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen
EP2755985B1 (de) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
AU719122B2 (en) 2000-05-04
US6248589B1 (en) 2001-06-19
EP0859833A4 (de) 2001-03-28
EP0859833B1 (de) 2006-03-01
WO1997012033A1 (en) 1997-04-03
EP0859833A1 (de) 1998-08-26
DE69635864D1 (de) 2006-04-27
DE69635864T2 (de) 2006-10-26
AU7200796A (en) 1997-04-17
US5981247A (en) 1999-11-09
CA2233309A1 (en) 1997-04-03
JP4191797B2 (ja) 2008-12-03
JPH11514862A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Borman et al. elF4G and its proteolytic cleavage products: effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs.
Kessler et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
Wirth et al. How a single Sindbis virus mRNA directs the synthesis of one soluble protein and two integral membrane glycoproteins
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
GB9722320D0 (en) Human cell cycle checkpoint proteins
HUP0002472A2 (hu) Izolált dendritikus sejtmembrán-fehérje gének
Barth et al. The oligomerization reaction of the Semliki Forest virus membrane protein subunits.
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
GB9810999D0 (en) Materials and methods relating to the expression of genes
Hansen et al. Presence of the cap-binding protein in initiation factor preparations from poliovirus-infected HeLa cells
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Robert et al. Interactions with tRNALys induce important structural changes in human immunodeficiency virus reverse transcriptase
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
ES2054743T3 (es) Muteina de beta-galactosidasa enzimaticamente inactiva e inmunologicamente activa.
AP2368A (en) Novel expression vectors and uses thereof.
EP0282330A3 (de) Verfahren zur Stimulierung der Genexpression
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
Skoging-Nyberg et al. MXI motif of Semliki Forest virus capsid protein affects nucleocapsid assembly

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties